Evaluating saliva levels in patients with different periodontal diseases

Assessment of Saliva Galectin-7, Galectin-10 and MMP-9 Levels In Individuals With Different Periodontal Diseases

This study is testing saliva samples from people with healthy gums, gingivitis, and periodontitis to see if certain proteins can help us understand their gum health better.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 20 Years to 60 Years
• Sex: All
• Sponsor: Izmir Katip Celebi University (Academic / other)
• Locations: 1 site (Izmir, Çiğli)
• Trial ID: NCT06186908 on ClinicalTrials.gov

What this trial studies

This study aims to detect levels of Galectin-10, Galectin-7, and MMP-9 in saliva samples from individuals with varying periodontal conditions, including healthy gums, gingivitis, and periodontitis. A total of 60 systemically healthy non-smokers will participate, providing saliva samples and undergoing full-mouth clinical periodontal assessments. The study will utilize enzyme-linked immunosorbent assay (ELISA) to analyze the saliva samples and correlate the findings with clinical parameters of periodontal diseases.

Who should consider this trial

Good fit: Ideal candidates include systemically healthy non-smokers with varying degrees of periodontal disease.

Not a fit: Patients with systemic health issues, smokers, or those on continuous medication may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic methods for periodontal diseases based on saliva biomarkers.

How similar studies have performed: While there is ongoing research in salivary biomarkers for periodontal diseases, this specific approach focusing on Galectin-10, Galectin-7, and MMP-9 levels is relatively novel.

Eligibility criteria

Inclusion Criteria:

* Systemically healthy (The determination of healthy volunteers will be based on the statements of the patients in the anamnesis. No additional examinations will be made.)
* At least twenty permanent teeth in the mouth
* Non-smoker
* No medication for continuous use
* Those who have not used antibiotics, anti-inflammatory and systemic corticosteroid drugs in the last 6 months.
* Not in pregnancy or lactation period.
* For the periodontitis group that has not received periodontal treatment in the last 6 months
* For the periodontitis group; According to the evaluation made in 6 regions of each tooth, individuals with 30% or more bleeding on probing area, at least 2 teeth not adjacent to each quarter jaw with a depth of 5 mm or more and 4 mm or more attachment loss, coronal 1/3 and more on radiography (horizontal and / or vertical) bone loss
* For the gingivitis group; According to the evaluation made in 6 regions of each tooth, individuals with 10% or more bleeding on probing area, having a probing depth of less than 4mm and no attachment loss
* For healthy group; According to the evaluation made in 6 regions of each tooth,individuals with less than 10% bleeding on probing area, having a probing depth less than 4mm and no loss of attachment were included in the study.

Exclusion Criteria:

* Any oral or systemic disease
* Regularly using a systemic medication
* During pregnancy or lactation
* Received periodontal treatment within the last 6 months.
* Those who received antibiotic, anti-inflammatory or systemic corticosteroid medication in the last 6 months
* Smokers are not included in the study

Where this trial is running

Izmir, Çiğli

• Izmir Katip Çelebi University Department of Periodontology — Izmir, Çiğli, Turkey (Türkiye) (Recruiting)

Study contacts

• Study coordinator: Ceren Köksal, Research assistant

Conditions Periodontal Diseases